Orchestra BioMed Holdings Inc. (NASDAQ:OBIO) experienced a 3.5% gain in its share price on Monday after the company was added to both the Russell 3000 and the Russell 2000 indexes. The inclusion took effect following the U.S. market close on Friday as part of the 2026 Russell indexes reconstitution.
The Russell reconstitution process captures the 4,000 largest U.S. companies as of April 30, ranking those companies by total market capitalization. Entry into the Russell 3000 Index carries a series of index placements - including automatic membership in the small-cap Russell 2000 Index and placement in the corresponding growth and value style indexes - that remain effective until the next semi-annual reconstitution.
Russell indexes are widely used by investment managers and institutional investors for both index funds and as benchmarks for active strategies. The indexes’ U.S. benchmarks are used to reference a large pool of assets, with about $12.2 trillion in assets reportedly benchmarked to Russell’s U.S. indexes.
Orchestra BioMed is a biomedical firm that develops medical device technologies in partnership with global device companies. According to the company description, it has two flagship product candidates that are currently undergoing pivotal clinical trials.
FTSE Russell determines Russell index membership primarily through objective rankings by market capitalization and by assessing style attributes. That methodology underpins the annual reconstitution that led to Orchestra BioMed’s recent inclusion.
For market participants and index-tracking funds, the reconstitution process and the resulting index changes are mechanical and rule-driven, with membership status carried forward until the next scheduled re-evaluation. The company will remain part of the Russell indexes until that next semi-annual reconstitution.
Context note - The firm’s inclusion is tied directly to the objective market-cap ranking used in the reconstitution and the company’s current development pipeline, which includes pivotal-stage clinical programs for two lead product candidates.